<DOC>
	<DOCNO>NCT02416466</DOCNO>
	<brief_summary>This open label fix dose phase Ib anti-CEA CAR-T cell hepatic artery infusion yttrium-90 SIR-Spheres patient CEA-expressing liver metastasis .</brief_summary>
	<brief_title>CAR-T Hepatic Artery Infusions Sir-Spheres Liver Metastases</brief_title>
	<detailed_description>Patients undergo leukapheresis peripheral blood mononuclear cell purify . T cell activate re-engineered express chimeric antigen receptor ( CARs ) specific CEA . Cells expanded culture return patient percutaneous hepatic artery infusion specific cell dos . Prior first dose , patient undergo diagnostic angiography verify suitable arterial anatomy . Three anti-CEA CAR-T dos one SIR-Sphere dose per patient plan 2-week interval . Low dose interleukin-2 give via ambulatory infusion pump 6 weeks.Normal liver tumor biopsy obtain time initial diagnostic angiogram final infusion session .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patient histologically confirm diagnosis CEA+ adenocarcinoma liver metastasis . Patient must either histologic confirmation liver metastases histologic documentation primary tumor definitive radiologic evidence liver involvement . Measurable disease require lesion &gt; 1.0 cm CT. Soluble CEA acceptable sole measure disease . Limited extrahepatic disease acceptable confine lung peritoneal cavity . Tumor must CEAexpressing demonstrate elevated serum CEA level ( â‰¥10ng/ml ) immunohistochemistry biopsy specimen . Archived tissue acceptable determination CEA expression . Patient must least 18 year age . Patient able understand sign inform consent . Patient life expectancy great four month . Patient fail least one line standard systemic chemotherapy unresectable disease . Patient performance status 0 1 ( ECOG ) . Patient adequate organ function define protocol . Acceptable hepatic vascular anatomy determine CT , MR , conventional angiography . A nuclear medicine study perform document absence significant hepaticpulmonary shunt ( &lt; 20 % ) . Female patient childbearing age test pregnancy . Pregnant patient exclude study . Males actively seek child make aware unknown risk study protocol human sperm need practice birth control . Patients serious unstable renal , hepatic , pulmonary , cardiovascular , endocrine , rheumatologic , allergic disease base history , physical exam laboratory test exclude , outline section 5.2.8 . Patients active clinical disease cause CMV , hepatitis B C , HIV tuberculosis exclude study . Patients cytotoxic and/or radiation therapy within 4 week prior entry trial 4 week prior infusion exclude . Patients concurrent malignancy exclude . Patients require systemic steroid exclude . Patients unsuitable hepatic vascular anatomy exclude study . Patients extrahepatic metastatic disease beyond lung abdominal/ retroperitoneal lymph node . Patients &gt; 50 % liver replacement time treatment exclude . Previous external beam radiotherapy liver . Portal vein thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Pancreas cancer</keyword>
	<keyword>Carcinoembryonic antigen</keyword>
	<keyword>CAR-T</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>